The reverse takeover company Hunter Capital RTO1 reports, as expected, no revenue and a negative result for the second quarter, while work on the planned reverse takeover of ResoTher Pharma continues.Net sales amounted to the expected SEK 0 million.Ebitda came to SEK -0.05 million. Cash and cash equivalents amounted to SEK 0.5 million at the end of the quarter.CEO Jacob Eriksson says that the process surrounding the planned reverse takeover of ResoTher Pharma is progressing and that the company’s assessment of the strategic rationale behind the transaction remains unchanged."We are now entering the next phase of the year with continued full focus on advancing the process with ResoTher Pharma. Although a number of steps remain before a transaction can be completed, we are satisfied with the progress so far and look forward to keeping the market updated as the process progresses," he writes in the report. The transaction remains conditional on, among other things, completed due diligence, regulatory approvals, financing and relevant shareholder decisions. The company is entering the next phase of the year with continued focus on advancing the process.No forecast is provided.